Retatrutide
$105.00
Retatrutide is an investigational peptide currently being evaluated as a triple receptor agonist (GLP-1, GIP, and glucagon). It has been investigated in preclinical and clinical research for its potential role in weight loss and metabolic regulation. Scientific interest has centered on how multi-agonist peptides may influence energy balance, glucose pathways, and body composition.
Areas of Scientific Interest
- Weight Regulation — Retatrutide has been studied in animal and clinical research for its impact on energy balance and appetite pathways.
- Metabolic Signaling — Investigations have explored interactions with GLP-1, GIP, and glucagon receptors in metabolic contexts.
- Endocrine Pathways — Research has examined the role of incretin receptor activation in glucose homeostasis and related functions.
Chemical Identity and Properties
- Molecular Formula: C₃₇₆H₅₉₀N₁₀₂O₁₁₆S₂
- Molecular Weight: ~8.0 kDa
- Sequence: Synthetic peptide (GLP-1/GIP/Glucagon receptor agonist)
- Appearance: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Storage: Store in a cool, dry environment; reconstitute only under appropriate laboratory conditions.
Selected Preclinical and Clinical Research
- NEJM (2023) — Reported phase 2 findings in obesity research involving investigational triple agonists.
- The Lancet (2023) — Described clinical outcomes of incretin-based multi-agonists in metabolic disorder studies.
- Nature Medicine (2024) — Sub-analysis of triple agonist mechanisms in relation to weight and glucose parameters.
- Cell Metabolism (2022) — Preclinical study of multi-receptor activation in animal models.
Important Notice
This compound is offered for laboratory research purposes only.
- Not for human consumption, medical, or veterinary use.
- No therapeutic or diagnostic applications are approved.
- All references to research are provided solely for educational context.